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OBJECTIVES: The study objective was to estimate cost effec-
tiveness of exemestane adjuvant treatment compared to tamox-
ifen for early-stage oestrogen-receptor-positive breast cancer
after 2–3 years treatment with tamoxifen in postmenopausal
women in Finland. METHODS: The analyses are based on the
Intergroup Exemestane Study (IES) results. According to the
IES exemestane improved disease-free survival, and decreased
risk of distant recurrence and contralateral breast cancer. A
Markov model was used to calculate costs and health outcomes
over patients’ lifetime period. The Finnish model adaptation
was carried out by populating the model with country-speciﬁc
current care practices, costs and mortality statistics. The costs
were included from societal perspective. The health state utili-
ties used in the model were taken from a range of international
studies. Health outcomes were assessed in terms of life years,
QALYs and disease-free life years gained. Probabilistic sensitiv-
ity analysis, with 1000 repeated simulations, was performed to
test robustness of the model parameters and assumptions.
RESULTS: The base case analysis resulted in incremental
16,185 EUR/QALY gained with exemestane versus tamoxifen.
The incremental cost per life year gained was 15,456 EUR
whereas it was 11,858 EUR per disease-free life year gained.
Based on the probabilistic sensitivity analysis there is a 67%
chance that exemestane is cost-effective alternative to tamox-
ifen at a value of 20,000 EUR/QALY gained, increasing to 90
percent if the decision maker is willing to pay 30,000 EUR.
CONCLUSION: The strategy of switching early-stage post-
menopausal breast cancer patients to exemestane following
two-to-three years of treatment with tamoxifen is a cost effec-
tive alternative compared to standard tamoxifen therapy taken
for ﬁve years in Finland.
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OBJECTIVES: This economic evaluation assesses the cost-
effectiveness of rituximab added as maintenance therapy once
every three months for two years after induction chemotherapy
for patients with relapsed/refractory follicular lymphoma in
Sweden, primarily based on data from the EORTC20981 trial.
METHODS: The economic model evaluates the incremental
cost and effectiveness of rituximab maintenance therapy versus
observation alone. A hypothetic patient cohort, aged 55 years
at the start of simulation, was followed in a state-transition
Markov model in monthly cycles over a period of 30 years.
Primary clinical endpoints were quality-adjusted life-years
(QALYs) and life-years gained (LYG). Progression-free and
overall survival data from the EORTC20981 trial were used to
calculate model state transitions. The analysis was made from
the perspective of the health care provider, including direct
medical costs presented in €2006 value. Effects and costs were
discounted at a 3% annual rate. One-way sensitivity analyses
were performed to test the stability of the results and identify
input parameters with particular inﬂuence on the results. A
probabilistic sensitivity analysis was performed to test the joint
instability of the model parameters. RESULTS: The calculations
showed that rituximab maintenance therapy was associated
with an incremental cost per QALY gained of €12,600 and an
incremental cost per LYG of €11,200. The average discounted
life expectancy in the rituximab group was 1.0 years longer
than with observation (5.96 versus 4.94). Rituximab mainte-
nance was associated with an additional 0.89 QALYs and total
costs per patient were €11,500 higher in the treatment arm,
compared to observation. The cost difference was mainly
attributable to cost and administration of the study drug. Sen-
sitivity analyses showed that the results were stable. CONCLU-
SION: The results indicate that maintenance treatment with
rituximab after induction therapy for patients with relapsed/
refractory follicular lymphoma in Sweden is cost-effective as
compared to observation alone.
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OBJECTIVES: Tegafur with uracil (Uftoral) is one of two oral
ﬂuoropyrimidine therapies approved by NICE for the ﬁrst-line
treatment of metastatic colorectal cancer. The other therapy is a
5-ﬂuorouracil pro-drug, capecitabine. The purpose of this study
was to compare the cost-effectiveness of tegafur with uracil
(when prescribed with folinic acid) against capecitabine
and other standard intravenous 5-ﬂuorouracil regimens.
METHODS: A literature review was conducted to assess the
relative clinical effectiveness of the different therapies under
assessment. A similar assessment was completed by Ward et al.
Costs were calculated from the UK NHS perspective for the full
cost of treatment included drug acquisition, drug administration,
and the treatment of adverse events. A cost minimisation analysis
was utilised. Direct randomised controlled trial comparisons of
the oral therapies with infusional 5-ﬂuorouracil schedules were
not available, though this assumes that all treatments are of equal
efﬁcacy. RESULTS: The cost-minimisation analysis showed that
treatment costs for a 12-week course of capecitabine (2132)
and tegafur with uracil (1788) were lower than costs for the
intravenous Mayo regimen (3593) and infusional regimens on
the de Gramont (6255) and Modiﬁed de Gramont (3485)
schedules over the same treatment period. For tegafur with
uracil, this represents a cost saving of 343 versus capecitabine
and 1696 versus the modiﬁed de Gramont. CONCLUSION:
The two oral therapies approved by NICE both result in lower
costs to the NHS than intravenous therapies. Tegafur with uracil
represents cost savings both per patient, but signiﬁcant cost
savings can be accrued when extrapolated over the whole poten-
tial patient population. Differences in this study are primarily
driven by drug acquisition cost. This study does not take into
account hand and foot syndrome which is a prominent side effect
in all treatments except tegafur with uracil and results in resource
utilisation and nurse time.
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